Comparison of Injection Site Pain Experience for Semaglutide and Dulaglutide sc

Phase 4

Completed

Conditions: Overweight
Healthy Volunteers
Diabetes Mellitus, Type 2
Obesity

Interventions: Drug: Semaglutide
Drug: Dulaglutide

Registration Number: NCT04189848

Lead Sponsor: Novo Nordisk A/S

Brief Summary: This study in healthy men and women looks at the injection site experience of semaglutide and dulaglutide given subcutaneously (s.c., under the skin). Participants will receive 1 dose of semaglutide 0.25 mg and 1 dose of dulaglutide 0.75 mg on the same day. The 2 injections will be given at least 30 minutes apart, one in each side of the stomach. Participants will be in the clinic research center for 1 day. A follow-up phone call will take place between 4 and 5 weeks after the injections were given.

Detailed Description: Not available

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 104

Inclusion Criteria

Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial.
Male or female, aged 18-75 years (both inclusive) at the time of signing informed consent.
Body mass index equal to or above 25.0 kg/m^2.
Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the Investigator.

Exclusion Criteria

Known or suspected hypersensitivity to trial product(s) or related products.
Previous participation in trial INS-4603, INS-4582 or NN9535-4648. Participation is defined as having received investigational product.
Female who is pregnant, breast-feeding or intends to become pregnant within 4 weeks of Day 1 or is of childbearing potential and not using highly effective contraceptive methods.
Participation in a drug study within 60 days prior to drug administration in the current trial OR participation in more than 4 other drug studies in the 12 months prior to drug administration in the current trial.
Any disorder which in the Investigator's opinion might jeopardise subject's safety, evaluation of results, or compliance with the protocol.
Glycosylated haemoglobin (HbA1c) equal to or above 6.5 % (48 mmol/mol) at screening.
Supine blood pressure at screening (after resting for 5 minutes or longer) outside the range of 90-160 mmHg for systolic or 45-89 mmHg for diastolic.
Supine pulse rate (as part of vital signs) outside the range of 40-100 beats/min after resting for 5 minutes or longer at screening.
Use of prescription medicinal products or non-prescription drugs or herbal products, except routine vitamins, topical medication, contraceptives and occasional use of paracetamol (not allowed within 24 hours prior to drug administration), within 14 days prior to Day 1.
Diagnostic test results positive for HIV-1 or HIV-2 infection.
Diagnostic test results positive for active hepatitis B or hepatitis C infection.
Mental incapacity, language barriers, or unwillingness to comply with the requirements of the protocol, which may preclude adequate understanding or cooperation during the trial as judged by the Investigator.
Average intake of more than 21 units of alcohol per week for male subjects and more than 14 units per week for female subjects: 1 unit of alcohol equals approximately 250 mL of beer, 100 mL of wine, or 35 mL of spirits).
Positive drug and alcohol screen (opiates, methadone, cocaine, amphetamines [including ecstasy], cannabinoids, barbiturates, benzodiazepines, tricyclic antidepressants, and alcohol) at screening and admission to the clinical research centre.
Use of tobacco and nicotine products, defined as any of the below:
Smoking more than 1 cigarette or the equivalent per day on average.
Not able or willing to refrain from smoking and use of nicotine substitute products during the in-house period.
Blood donation, plasma donation, or blood draw
In excess of 400 mL within the past 90 days prior to the day of screening
In excess of 50 mL within the past 30 days prior to the day of screening
Personal or first-degree relative(s) history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma.
Subjects with a history of malignant neoplasms within the past 5 years prior to screening will be excluded from the trial.
Presence or history of pancreatitis (acute or chronic; as declared by the subject or reported in the medical records).
Subject is not able to understand and read English or Dutch, or subject is not able to understand and comply with the trial requirements.
Subject depends on the Sponsor, the Investigator, or the study centre, or subject is the Investigator or any sub-investigator, research assistant, pharmacist, study coordinator, other staff, or relative thereof directly involved in the conduct of the trial.
Vulnerable subject (e.g. person kept in detention) who may have an increased likelihood of being wronged or of incurring additional harm.

Study & Design

Study Type: INTERVENTIONAL

Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Semaglutide followed by dulaglutide	Semaglutide	The 2 treatments will be administered at least 30 minutes apart, one in each side of the stomach
Dulaglutide followed by semaglutide	Semaglutide	The 2 treatments will be administered at least 30 minutes apart, one in each side of the stomach
Semaglutide followed by dulaglutide	Dulaglutide	The 2 treatments will be administered at least 30 minutes apart, one in each side of the stomach
Dulaglutide followed by semaglutide	Dulaglutide	The 2 treatments will be administered at least 30 minutes apart, one in each side of the stomach

Primary Outcome Measures

Name	Time	Method
Intensity of Injection Site Pain	1 minute after each injection (Day 1)	The intensity of injection site pain was measured on a visual analogue scale (VAS). The VAS consists of a horizontal 100 millimeters (mm) line where 0 mm corresponded to no pain and 100 mm corresponded to unbearable pain. After each injection, the participants rated their pain perception at the VAS by marking a vertical line across the 100 mm horizontal line. The distance (mm) between the endpoint "no pain" and the vertical line on the VAS was recorded and analysed.

Secondary Outcome Measures